SLC5A2 and diabetes mellitus: Among the available antidiabetic drug classes, sodium–glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) have demonstrated remarkable efficacy in lowering the incidence of major adverse cardiovascular events, signifying their significant impact on the management of diabetes and its associated cardiovascular complications [16,17].